![Zuzana Zachar](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Zuzana Zachar
Technik-/Wissenschafts-/F&E-Leiter bei Cornerstone Pharmaceuticals, Inc.
Profil
Zuzana Zachar is currently working as a Research Director at Cornerstone Pharmaceuticals, Inc. She holds a doctorate degree from Stony Brook University and a graduate degree from the University of Illinois.
Aktive Positionen von Zuzana Zachar
Unternehmen | Position | Beginn |
---|---|---|
Cornerstone Pharmaceuticals, Inc.
![]() Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Technik-/Wissenschafts-/F&E-Leiter | 17.04.2009 |
Ausbildung von Zuzana Zachar
University of Illinois | Graduate Degree |
Stony Brook University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Cornerstone Pharmaceuticals, Inc.
![]() Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Commercial Services |